baxinteraction.co.uk
Bax Interaction Ltd. - Marketing consultants to accountants, recruitment companies, not-for-profits
http://baxinteraction.co.uk/clients.php
A targeted new initiative from Bax Interaction to transform your marketing effectiveness. Ldquo;We operate in a niche industry so obtaining relevant research of value is a challenge. Steve’s research delivered tailored insight and recommendations, enabling us to focus our resources in areas where they produce maximum return for our efforts.”. James Gilbert, Managing Director, Pixel Power Limited. This is a selection of the many clients we have worked with across a broad range of business sectors:. A full...
isddteach.sdv.univ-paris-diderot.fr
Master IN SILICO DRUG DESIGN
http://isddteach.sdv.univ-paris-diderot.fr/fr/equipe.html
Spécialité MMis : Analyse in silico des complexes médicaments-macromolécules biologiques. Spécialité IsMB : Design in silico des molécules bioactives. S1 Univ. Paris Diderot. S2 Univ. Paris Diderot. S1 Univ. Strasbourg. S2 Univ. Milan. Arrêtés Jury/Commission pédagogique. Modalités évaluation. S3 Univ. Paris Diderot. Arrêtés Jury/Commission pédagogique. Modalités évaluation. Equipe pédagogique Master 1. Equipe pédagogique Master 2. Equipe pédagogique - Master 1. MC - Paris Diderot/P7) - UMR ECOSYS. GASTR...
morphosys.de
Bestehende Partnerschaften | MorphoSys AG
https://www.morphosys.de/partnerschaften/bestehende-partnerschaften
MorphoSys auf einen Blick. Engineering the Medicines of Tomorrow. Discovery, Alliances and Technologies. Kompetent in der Arzneimittelentwicklung. Herstellung, Chemie- und Produktionskontrolle. Investition in die Medikamente von morgen. Im Folgenden sind die Abkommen der MorphoSys AG kurz beschrieben, die spürbare finanzielle Auswirkungen gehabt haben bzw. in zukünftigen Geschäftsjahren haben könnten (in alphabetischer Reihenfolge). MorphoSys und Astellas Pharma. Wurde Ende 2007 eingestellt. Es befin...
ibdnewstoday.com
Galapagos Announces Last Patient Has Been Randomized in Crohn's Disease Study With Filgotinib
http://ibdnewstoday.com/2015/08/07/galapagos-announces-last-patient-randomized-crohns-disease-study-filgotinib
This is a short description about myself and what this site is about. I hope you enjoy being here! IBD Signs & Symptoms. Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib. August 7, 2015. August 7, 2015. By Daniela Semedo, PhD. Click here to receive IBD news via e-mail. The trial is assessing the safety and efficacy of filgotinib,. A Janus kinase inhibitor. With selectivity for subtype JAK1. The company is expecting to announce the study’s primary endpoin...
bryangarnier.com
bryan-garnier-galapagos-ipo | Bryan, Garnier & Co
http://www.bryangarnier.com/en/blog/article/bryan-garnier-galapagos-ipo
Bryan, Garnier and Co's News. Bryan, Garnier and Co announces the successful $275m IPO of Galapagos NV, the largest Nasdaq IPO of European biotech. May Thursday 14, 2015. London, May 14th, 2015 Bryan, Garnier and Co, the pan-European investment bank for growth companies, announces the successful $275 million Nasdaq IPO of Galapagos NV, a major European clinical-stage biotechnology company. Bryan, Garnier and Co is the only European investment bank in the IPO syndicate. The. Bryan, Garnier and Co confirms...
bryangarnier.com
bryan-garnier-galapagos-filing-for-nasdaq | Bryan, Garnier & Co
http://www.bryangarnier.com/en/blog/article/bryan-garnier-galapagos-filing-for-nasdaq
Bryan, Garnier and Co's News. Bryan, Garnier and Co announces the filing of European Biotech Galapagos for a Nasdaq IPO. April Friday 17, 2015. The registration statement contains a proposed maximum aggregate offering price of $150m. Morgan Stanley, Credit Suisse, and Cowen and Company are acting as joint book-running managers, and Nomura and Bryan, Garnier and Co are acting as co-managers, for the proposed global offering. About Bryan, Garnier and Co. Bryan, Garnier and Co advises MisterFly on a 20m Equ...
bryangarnier.com
bryan-garnier-galapagos-nasdaq-over-allotment | Bryan, Garnier & Co
http://www.bryangarnier.com/en/blog/article/bryan-garnier-galapagos-nasdaq-over-allotment
Bryan, Garnier and Co's News. Bryan, Garnier and Co announces that the total proceeds of Galapagos IPO on Nasdaq, the largest Nasdaq IPO of a European biotech, have been raised to $317m following the full exercise of over-allotment option. May Tuesday 19, 2015. Bryan, Garnier and Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura. Bryan, Garnier and Co confirms its leading position in the financing of the European emerging bioph...
SOCIAL ENGAGEMENT